Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 4:44 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 99 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Alphagan Clear all
Completed Phase 3 Interventional

Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension

NCT00332384
View directory record Official record
Conditions
Ocular Hypertension
Interventions
brimonidine/timolol fixed combination
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
573 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2001
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated May 30, 2011 · Synced Oct 20, 2026, 4:44 PM EDT
Completed Phase 4 Interventional Results available

Internet Surveys and Their Impact on Adherence for Rosacea

NCT03048058
View directory record Official record
Conditions
Rosacea
Interventions
brimonidine topical gel 0.33% & survey, brimonidine topical gel 0.33% & SOC
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 10, 2018 · Synced Oct 20, 2026, 4:44 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Study Evaluating the Safety and Efficacy of Brimonidine Tartrate Ophthalmic Solution in Adult and Geriatric Subjects

NCT01675609
View directory record Official record
Conditions
Ocular Redness
Interventions
Placebo, Brimonidine tartrate 0.025%
Drug
Lead sponsor
Eye Therapies, LLC
Industry
Eligibility
40 Years and older
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2012
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 31, 2014 · Synced Oct 20, 2026, 4:44 PM EDT
Completed Phase 4 Interventional Results available

Circadian Ocular Perfusion Pressure and Ocular Blood Flow

NCT00800540
View directory record Official record
Conditions
Glaucoma
Interventions
Brinzolamide 10 mg/ml/Timolol 5 mg/ml eye drops suspension, Brimonidine 20 mg/ml/Timolol 5 mg/ml eye drops solution
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Mar 22, 2013 · Synced Oct 20, 2026, 4:44 PM EDT
Terminated Phase 3 Interventional Results available

Study of Brimonidine Tartrate Nanoemulsion Eye Drops in Patients With Ocular Graft-vs-Host Disease

NCT03591874
View directory record Official record
Conditions
Graft Versus Host Disease, Ocular Surface Disease, oGVHD, Ocular Graft vs Host Disease, Brimonidine Tartrate, Lubricant Eye Drops, Ophthalmic Solutions, Graft vs Host Disease
Interventions
Brimonidine Tartrate, Placebos
Drug
Lead sponsor
Ocugen
Industry
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
13
States / cities
Phoenix, Arizona • Palo Alto, California • Atlanta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2022 · Synced Oct 20, 2026, 4:44 PM EDT
Completed No phase listed Observational

Intraocular Pressure During Spine Surgery

NCT00593359
View directory record Official record
Conditions
Intraocular Pressure
Interventions
Not listed
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 23, 2016 · Synced Oct 20, 2026, 4:44 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Brimonidine Eye Drops for Treatment of Ocular Graft-vs-Host Disease (oGVHD)

NCT02975557
View directory record Official record
Conditions
Dry Eye, Ocular Graft vs Host Disease, Meibomian Gland Dysfunction
Interventions
Brimonidine 0.15%, Brimonidine 0.075%, Placebo
Drug
Lead sponsor
Sandeep Jain, MD
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 8, 2019 · Synced Oct 20, 2026, 4:44 PM EDT
Completed Phase 3 Interventional Results available

"Efficacy and Safety of Brimonidine Tartrate Preservative-Free Formulation in Adults With Ocular Redness"

NCT05360784
View directory record Official record
Conditions
Ocular Redness
Interventions
Brimonidine tartrate ophthalmic solution 0.025% preservative-free formulation, Lumify® (brimonidine tartrate ophthalmic solution 0.025%)
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
6
States / cities
Colorado Springs, Colorado • Louisville, Kentucky • Andover, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2024 · Synced Oct 20, 2026, 4:44 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of Safety and Efficacy of PDP-716

NCT03450629
View directory record Official record
Conditions
Open Angle Glaucoma, Ocular Hypertension
Interventions
Brimonidine Tartrate Ophthalmic Suspension, Brimonidine Tartrate Ophthalmic Solution
Drug
Lead sponsor
Sun Pharma Advanced Research Company Limited
Industry
Eligibility
2 Years and older
Enrollment
682 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
47
States / cities
Chandler, Arizona • Prescott, Arizona • Sun City, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2022 · Synced Oct 20, 2026, 4:44 PM EDT
Completed No phase listed Observational

Preferences & Treatment Satisfaction Drivers in Rosacea Patients

NCT02602470
View directory record Official record
Conditions
Rosacea
Interventions
Azelaic Acid Gel including: Finacea (Azelaic Acid Gel 15%, BAY39-6251), Azelaic Acid Cream, Metronidazole gel, Metronidazole cream, Metronidazole Emulsion, Metronidazole Lotion, Brimonidine Tartrate Gel
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 1, 2020 · Synced Oct 20, 2026, 4:44 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Efficacy Study of BRIMOCHOL™, BRIMOCHOL™ F, and Carbachol in Subjects With Emmetropic Phakic and Pseudophakic Presbyopia

NCT04774237
View directory record Official record
Conditions
Presbyopia
Interventions
BRIMOCHOL™, BRIMOCHOL™ F, Carbachol
Drug
Lead sponsor
Visus Therapeutics
Other
Eligibility
45 Years to 80 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
3
States / cities
Glendale, California • Newport Beach, California • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 20, 2026, 4:44 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Additivity Study: Additive Effect on Eye Pressure of Azopt and Alphagan P to Travatan

NCT00121147
View directory record Official record
Conditions
Open Angle Glaucoma, Ocular Hypertension, Pseudoexfoliation Syndrome
Interventions
Travatan, Azopt, Alphagan P
Drug
Lead sponsor
Hermann Eye Center
Other
Eligibility
35 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2005
U.S. locations
21
States / cities
Los Angeles, California • Hamden, Connecticut • Gainesville, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2006 · Synced Oct 20, 2026, 4:44 PM EDT
Terminated Phase 2 Interventional Results available

A Safety and Efficacy Study of Brimonidine Intravitreal Implant in Geographic Atrophy Secondary to Age-related Macular Degeneration

NCT02087085
View directory record Official record
Conditions
Geographic Atrophy, Macular Degeneration
Interventions
400 µg Brimonidine Implant, Sham
Drug · Other
Lead sponsor
Allergan
Industry
Eligibility
55 Years and older
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
23
States / cities
Phoenix, Arizona • La Jolla, California • Mountain View, California + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Oct 20, 2026, 4:44 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Effect of Brimonidine

NCT03959176
View directory record Official record
Conditions
Intraocular Pressure
Interventions
Brimonidine, Tropicamide, Phenylephrine Ophthalmic Product
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 50 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 1, 2024 · Synced Oct 20, 2026, 4:44 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study Comparing CD07805/47 Gel 0.5% to Azelaic Acid Gel 15% in Subjects With Erythema of Rosacea

NCT01659853
View directory record Official record
Conditions
Erythema, Rosacea
Interventions
CD07805/47 gel 0.5%/CD07805/47 Vehicle, azelaic acid gel 15%
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
4
States / cities
Evansville, Indiana • Louisville, Kentucky • Austin, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2022 · Synced Oct 20, 2026, 4:44 PM EDT
Completed Phase 4 Interventional

Brimonidine 0.1% Versus Brinzolamide 1% as Adjunctive Therapy to Latanoprost 0.005%

NCT00440141
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
latanoprost 0.005% eye drops and brimonidine 0.1% eye drops, latanoprost 0.005% eye drops and brinzolamide 1.0% eye drops
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 2, 2008 · Synced Oct 20, 2026, 4:44 PM EDT
Completed Phase 4 Interventional Results available

Finacea 15% and Brimonidine 0.33% Gel in the Treatment of Rosacea - A Pilot Study

NCT02147691
View directory record Official record
Conditions
Acne Rosacea
Interventions
Azelaic acid 15%, Brimonidine 0.33%
Drug
Lead sponsor
Derm Research, PLLC
Other
Eligibility
18 Years to 85 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Sep 30, 2015 · Synced Oct 20, 2026, 4:44 PM EDT
Completed Phase 1 Interventional

Study Evaluating the Safety and Intraocular Pressure (IOP) Lowering Response of Brimonidine Tartrate Ophthalmic Solution in Subjects With Open Angle Glaucoma or Ocular Hypertension

NCT01687426
View directory record Official record
Conditions
Glaucoma and Ocular Hypertension
Interventions
Brimonidine Tartrate 0.025%, Vehicle
Drug
Lead sponsor
Eye Therapies, LLC
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Winchester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 25, 2012 · Synced Oct 20, 2026, 4:44 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Effect of Netarsudil vs Brimonidine in NTG Patients on Latanoprost

NCT06449352
View directory record Official record
Conditions
Normal Tension Glaucoma
Interventions
Netarsudil, Brimonidine
Drug
Lead sponsor
Westlake Eye Specialists
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
4
States / cities
Austin, Texas • Killeen, Texas • Kyle, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Oct 20, 2026, 4:44 PM EDT
Completed Phase 3 Interventional Results available

Study of Brimonidine Tartrate Nanoemulsion Eye Drop Solution in the Treatment of Dry Eye Disease (DED)

NCT03785340
View directory record Official record
Conditions
Dry Eye
Interventions
Brimonidine Tartrate, Placebos
Drug
Lead sponsor
Ocugen
Industry
Eligibility
18 Years and older
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
16
States / cities
Newport Beach, California • Rancho Cordova, California • Pompano Beach, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2022 · Synced Oct 20, 2026, 4:44 PM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Brimonidine for Intraoperative Hemostasis

NCT05480098
View directory record Official record
Conditions
Dermatochalasis of Eyelid, Ptosis, Eyelid, Ectropion, Entropion
Interventions
Brimonidine Topical
Drug
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Jan 15, 2025 · Synced Oct 20, 2026, 4:44 PM EDT
Completed Early Phase 1 Interventional Results available

Aqueous Humor Dynamics and Brimonidine

NCT01144494
View directory record Official record
Conditions
Intraocular Pressure
Interventions
Brimonidine, Artificial tears
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Nov 28, 2023 · Synced Oct 20, 2026, 4:44 PM EDT
Terminated Phase 4 Interventional Results available

Safety and Efficacy of SIMBRINZA® BID as an Adjunctive to DUOTRAV®

NCT02730871
View directory record Official record
Conditions
Open-angle Glaucoma, Ocular Hypertension
Interventions
Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension, Brinzolamide/brimonidine vehicle, Travoprost 0.004%/timolol 0.5% solution
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated May 29, 2019 · Synced Oct 20, 2026, 4:44 PM EDT
Completed Phase 4 Interventional Results available

MirvasO Soolantra Association In the Treatment of Moderate to Severe rosaCea.

NCT02616250
View directory record Official record
Conditions
Rosacea
Interventions
Brimonidine 0.33% gel (Br), CD07805/47 (Br) placebo gel, Ivermectin 1% cream (IVM), CD5024 (IVM) placebo cream
Drug · Other
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
7
States / cities
Fort Smith, Arkansas • Rogers, Arkansas • Sacramento, California + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Oct 20, 2026, 4:44 PM EDT